{
  "schemaVersion": 2,
  "eyebrow": "Gastroenterology",
  "title": "Crohn Disease",
  "summary": "Crohn disease requires objective confirmation, phenotype-based risk assessment, steroid-sparing treatment, and longitudinal monitoring beyond symptoms. Ileocolonoscopy with biopsy establishes diagnosis and extent; biomarkers and cross-sectional imaging help detect ongoing inflammation, complications, and discordance between symptoms and disease activity.",
  "seoDescription": "Physician guide to Crohn disease diagnosis, objective monitoring, induction and maintenance principles, complications, surgery, and surveillance.",
  "clinicalQuestion": "How should physicians confirm, risk-stratify, treat, and objectively monitor Crohn disease while preventing avoidable complications?",
  "specialty": "Gastroenterology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "Crohn disease",
    "ileocolonoscopy",
    "fecal calprotectin",
    "cross-sectional imaging",
    "biologic therapy",
    "treat-to-target"
  ],
  "keyTakeaways": [
    "At presentation, ileocolonoscopy with biopsy is the first-line diagnostic test because it defines extent and provides histology needed to distinguish Crohn disease from infectious, drug-induced, and ischemic mimics. [3]",
    "Symptoms and serum CRP can underestimate active mucosal disease; fecal calprotectin is useful for triage and monitoring but is less reliable in isolated small-bowel disease. [15][16]",
    "Systemic corticosteroids are appropriate induction therapy for moderate-to-severe uncomplicated luminal disease but should not become maintenance therapy; extensive disease or poor prognostic features support early biologic consideration. [1]",
    "5-aminosalicylates have little to no role in Crohn disease management, including postoperative maintenance. [3]",
    "Persistent symptoms require confirmation of inflammatory activity before escalation; conversely, objective inflammation despite clinical improvement warrants reassessment because clinical indices and CRP do not reliably identify endoscopic remission. [16]"
  ],
  "sections": [
    {
      "id": "diagnostic-confirmation",
      "eyebrow": "Diagnosis",
      "heading": "Confirm disease and define inflammatory burden",
      "intro": "Establish anatomy, histology, and complications before committing to long-term immunosuppression.",
      "paragraphs": [
        "Use ileocolonoscopy with segmental biopsy as the first-line test at index presentation. It assesses colonic and terminal ileal extent and supplies histology, which remains particularly important for separating Crohn disease from infection, medication-related injury, ischemia, and other mimics before medical therapy is initiated. [3]",
        "Pair endoscopy with cross-sectional imaging when small-bowel extent, transmural inflammation, penetrating disease, obstruction, or extraluminal complications are suspected. In an uncertain presentation, fecal calprotectin can help determine whether ileocolonoscopy and imaging are warranted. [14] Capsule endoscopy is an adjunct for patients with high clinical suspicion of small-bowel Crohn disease; deep enteroscopy is not routine but can provide tissue when small-bowel sampling is required. [2]",
        "Obtain a baseline CBC and inflammatory markers, recognizing their limitations. Anemia and thrombocytosis are common hematologic abnormalities; CRP and ESR are standard acute-phase surrogates, but normal values do not exclude active disease in an individual patient. [15][22] Screen for iron, 25-hydroxyvitamin D, folate, and vitamin B12 deficiency. [14]"
      ],
      "bullets": [
        "Use fecal calprotectin or lactoferrin as adjunctive evidence of intestinal inflammation; low CRP and/or low calprotectin had a 99% negative predictive value for IBS in one meta-analysis summarized by ECCO. [15]",
        "Interpret a low fecal calprotectin cautiously in isolated ileal disease, where fecal markers may be less sensitive and correlate imperfectly with transmural inflammation. [15][16]",
        "When diagnosis remains uncertain after standard evaluation, capsule endoscopy may add diagnostic information in selected patients; obtain tissue by enteroscopy only when it will change diagnosis or management. [2][18]"
      ],
      "subsections": [],
      "table": {
        "caption": "Objective assessment tools and their principal clinical use in Crohn disease. [2][3][15][16]",
        "columns": [
          "Tool",
          "Best use",
          "Interpretive limitation"
        ],
        "rows": [
          [
            "Ileocolonoscopy with biopsy",
            "Initial confirmation, extent assessment, histologic diagnosis, and mucosal reassessment. [3][16]",
            "Does not fully characterize proximal small bowel or transmural/extraluminal disease. [14][16]"
          ],
          [
            "Cross-sectional imaging",
            "Assessment of small-bowel involvement and complications beyond the mucosa. [14]",
            "Does not replace biopsy-based diagnostic evaluation at presentation. [3]"
          ],
          [
            "Fecal calprotectin",
            "Triage for further investigation and serial assessment of inflammatory activity. [14][15]",
            "May be falsely reassuring in isolated small-bowel disease; individual thresholds are not uniform. [15][16]"
          ],
          [
            "CRP and ESR",
            "Serial adjuncts to assess inflammatory activity. [15]",
            "May not correlate with an individual patient's clinical or endoscopic disease activity. [16][22]"
          ]
        ]
      }
    },
    {
      "id": "treatment-principles",
      "eyebrow": "Medical Management",
      "heading": "Use induction therapy to gain control, then transition to durable steroid-sparing management",
      "intro": "Treatment selection should reflect inflammatory severity, extent, behavior, complications, and prior treatment exposure.",
      "paragraphs": [
        "For moderate-to-severe uncomplicated luminal Crohn disease, systemic corticosteroids are recommended for initial induction. Patients with extensive disease or poor prognostic features should be considered for earlier biologic therapy rather than repeated conventional-treatment cycles. [1] Corticosteroids should be viewed as induction agents, not a strategy for durable disease control.",
        "For mild-to-moderate disease, available evidence summaries describe budesonide, sulfasalazine, and dietary modifications as induction options, with treatment choice influenced by disease location and severity. [14] Do not extrapolate ulcerative colitis practice to Crohn disease: 5-aminosalicylates have little to no role in Crohn disease management, including postoperative maintenance. [3]",
        "For steroid-dependent or steroid-resistant disease, older ECCO guidance summarized in a quality review identifies azathioprine or mercaptopurine as first-line steroid-sparing options and methotrexate when purine analogues are ineffective or not tolerated; biologic therapy is appropriate when conventional therapy fails, is not tolerated, or disease is moderate to severe. [2][19] Contemporary agent selection requires current guideline and labeling review because the supplied evidence does not provide U.S. dosing, safety screening, or comparative positioning among biologics and small molecules."
      ],
      "bullets": [
        "Avoid repeated corticosteroid exposure as a substitute for maintenance therapy; recurrent steroid requirement should trigger reassessment of disease activity, complications, adherence, and a steroid-sparing plan. [1][2]",
        "Before immunomodulator or biologic treatment, obtain vaccination history and update vaccinations. Live vaccines should be administered at least 4 weeks before immunosuppression or at least 3 months after stopping it, and not during immunosuppressive therapy. [1]",
        "For adalimumab, adding an immunomodulator did not improve pooled induction or maintenance remission versus monotherapy, but was associated with lower odds of anti-adalimumab antibody development; infection tradeoffs remain relevant. [20]"
      ],
      "subsections": [
        {
          "heading": "Treat symptoms and objective inflammation as separate targets",
          "paragraphs": [
            "Clinical response and remission definitions are useful trial constructs but do not establish mucosal control. In Crohn disease, clinical remission is commonly defined as a Crohn's Disease Activity Index below 150, whereas endoscopic response is a greater than 50% decrease in the Simplified Endoscopic Score for Crohn's Disease; these outcomes should not be assumed to coincide. [5]"
          ],
          "bullets": [
            "Do not escalate solely for nonspecific symptoms without objective evidence of inflammatory activity; pain and bowel dysfunction may have noninflammatory contributors. [22]",
            "Do not accept symptom control alone as proof of remission when biomarkers, imaging, or endoscopy suggest ongoing disease. Clinical indices and CRP were not reliable for identifying endoscopic remission in an anti-TNF-treated cohort. [16]"
          ]
        }
      ],
      "table": {
        "caption": "Treatment decisions supported by the supplied evidence. [1][2][3][14][19][20]",
        "columns": [
          "Clinical situation",
          "Decision-supported approach",
          "Important qualification"
        ],
        "rows": [
          [
            "Moderate-to-severe uncomplicated luminal disease",
            "Use systemic corticosteroids for induction. [1]",
            "Consider early biologic therapy with extensive disease or poor prognostic features. [1]"
          ],
          [
            "Mild-to-moderate disease",
            "Budesonide, sulfasalazine, and dietary modifications are described induction options. [14]",
            "Location-specific selection and current guideline review are necessary; supplied sources do not provide dosing. [14]"
          ],
          [
            "Steroid-dependent or steroid-resistant disease",
            "Use a steroid-sparing strategy; azathioprine or mercaptopurine and, when needed, methotrexate are described conventional options. [2]",
            "Biologic therapy is appropriate after conventional-treatment failure, intolerance, or for moderate-to-severe disease. [19]"
          ],
          [
            "Consideration of 5-aminosalicylates",
            "Do not routinely use 5-aminosalicylates for Crohn disease. [3]",
            "The cited guideline also found no compelling role in postoperative maintenance. [3]"
          ]
        ]
      }
    },
    {
      "id": "monitoring-and-reassessment",
      "eyebrow": "Longitudinal Care",
      "heading": "Monitor objectively and investigate discordance",
      "intro": "Symptoms, biomarkers, endoscopy, and imaging answer different questions.",
      "paragraphs": [
        "Assess patients in remission regularly with clinical review plus CRP and/or fecal calprotectin as adjunctive markers. [15] A rise in fecal calprotectin should prompt evaluation for inflammatory recurrence, but decisions should account for disease location, baseline biomarker behavior, and alternative causes of symptoms or marker elevation.",
        "Endoscopy remains the reference standard for assessing mucosal activity and confirming mucosal healing, although it is invasive and costly. [16] Fecal calprotectin can reduce the need for repeated endoscopy in selected settings: in one study, a value of 250 micrograms/g or less predicted endoscopic remission defined as CDEIS 3 or less with sensitivity 94.1% and negative predictive value 96.6%, but specificity was 62.2% and positive predictive value 48.5%. [16] This threshold should not be treated as universally applicable.",
        "After intestinal resection, fecal calprotectin measurement has a potentially valuable role in monitoring recurrence. [24] One monitoring strategy evaluates fecal calprotectin at 3 months after surgery and considers earlier endoscopy if it rises, followed by endoscopic assessment after the initial postoperative evaluation. [17]"
      ],
      "bullets": [
        "Escalate evaluation for biomarker elevation despite minimal symptoms rather than assuming remission. [16]",
        "Evaluate ongoing symptoms with normal inflammatory assessment for noninflammatory causes before changing immunosuppressive therapy. [22]",
        "Use endoscopy and other diagnostic modalities when phenotype or diagnosis may have changed; initial endoscopy plus biopsy does not permanently settle classification in every patient. [16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical interpretation of common monitoring discordance. [15][16][22]",
        "columns": [
          "Finding",
          "Interpretation",
          "Next action"
        ],
        "rows": [
          [
            "Symptoms improve but fecal calprotectin remains elevated",
            "Clinical improvement may not reflect endoscopic remission. [16]",
            "Reassess inflammatory burden with disease-location-appropriate objective testing. [16]"
          ],
          [
            "Symptoms persist but CRP is normal",
            "Normal CRP does not exclude active Crohn disease in an individual patient. [22]",
            "Use fecal biomarkers, endoscopy, or imaging according to phenotype and suspected location. [14][15]"
          ],
          [
            "Low fecal calprotectin in suspected isolated ileal disease",
            "Fecal markers can have diminished value in small-bowel-restricted Crohn disease. [15][16]",
            "Do not exclude active disease solely on the biomarker; consider cross-sectional imaging or other appropriate evaluation. [14][16]"
          ]
        ]
      }
    },
    {
      "id": "complications-and-surgery",
      "eyebrow": "Complications",
      "heading": "Integrate surgery early when disease is localized or complications are not medically manageable",
      "intro": "Surgery is a disease-management option, not only a last resort.",
      "paragraphs": [
        "Consider surgery for localized disease and involve colorectal surgery promptly for life-threatening complications. Emergency surgery is indicated for intestinal perforation, refractory bleeding, or toxic megacolon; elective surgery is indicated for dysplasia or malignancy, refractory disease, or inability to tolerate long-term immunosuppression or other pharmacologic therapy. Laparoscopy is preferred when feasible. [2]",
        "Perianal and fistulizing disease requires control of infection followed by advanced medical therapy. [14] The supplied evidence does not provide procedural sequencing, drainage technique, antibiotic regimens, or biologic dosing; these decisions should be coordinated with an experienced multidisciplinary IBD and colorectal surgery team."
      ],
      "bullets": [
        "Suspect a structural or penetrating complication when symptoms are disproportionate, obstructive, systemic, or refractory to apparently appropriate anti-inflammatory therapy; obtain cross-sectional assessment as clinically indicated. [14]",
        "Use postoperative biomarker and endoscopic surveillance rather than symptom-based follow-up alone. [17][24]"
      ],
      "subsections": [],
      "table": {
        "caption": "Surgical indications described in Crohn disease consensus evidence. [2]",
        "columns": [
          "Setting",
          "Indication",
          "Management implication"
        ],
        "rows": [
          [
            "Emergency",
            "Perforation, refractory bleeding, or toxic megacolon. [2]",
            "Urgent surgical evaluation and operative management. [2]"
          ],
          [
            "Elective",
            "Dysplasia or malignancy, refractory course, or intolerance to long-term immunosuppression or other pharmacotherapy. [2]",
            "Discuss surgery as a planned therapeutic alternative; use laparoscopy when feasible. [2]"
          ],
          [
            "Localized disease",
            "Surgery should always be considered as an option. [2]",
            "Balance resection against expected medical-treatment burden and disease phenotype. [2]"
          ]
        ]
      }
    },
    {
      "id": "preventive-care",
      "eyebrow": "Preventive Care",
      "heading": "Address immunization, deficiencies, and colorectal cancer risk",
      "intro": "Preventive care should be built into every treatment transition.",
      "paragraphs": [
        "Document vaccination history at diagnosis and before immunomodulator or biologic therapy, then update vaccines as appropriate. Live vaccines should not be administered during immunosuppressive therapy; if feasible, give them at least 4 weeks before treatment initiation or at least 3 months after immunosuppression has stopped. [1]",
        "Monitor and correct nutritional and hematinic deficits, including iron, vitamin D, folate, and vitamin B12. [14] For colorectal cancer surveillance, an evidence summary notes that most guidelines recommend colonoscopy beginning 8 years after symptom onset, with subsequent intervals determined by additional risk factors. [14] The supplied evidence does not specify risk-stratified U.S. surveillance intervals."
      ],
      "bullets": [
        "Review preventive care before starting or changing immunosuppressive therapy rather than after treatment has begun. [1]",
        "Use disease extent and additional colorectal cancer risk factors to determine surveillance intensity after the initial 8-year time point. [14]"
      ],
      "subsections": [],
      "table": {
        "caption": "Preventive-care actions supported by the supplied evidence. [1][14]",
        "columns": [
          "Action",
          "When",
          "Evidence-supported detail"
        ],
        "rows": [
          [
            "Vaccination review",
            "At diagnosis and before immunomodulator or biologic therapy. [1]",
            "Update vaccines; avoid live vaccines during immunosuppressive therapy. [1]"
          ],
          [
            "Deficiency assessment",
            "Initial and ongoing care as clinically indicated. [14]",
            "Assess iron, 25-hydroxyvitamin D, folate, and vitamin B12. [14]"
          ],
          [
            "Colorectal cancer surveillance",
            "Approximately 8 years after symptom onset. [14]",
            "Subsequent monitoring depends on additional risk factors. [14]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Can normal CRP exclude active Crohn disease?",
      "answer": "No. CRP may not correlate with an individual patient's active disease or endoscopic status. Use fecal calprotectin, endoscopy, and/or cross-sectional imaging according to phenotype and suspected disease location. [15][16][22]"
    },
    {
      "question": "When is capsule endoscopy useful in suspected Crohn disease?",
      "answer": "Capsule endoscopy is an adjunct when there is a high index of suspicion for small-bowel Crohn disease. Deep enteroscopy is not routine but may be useful when small-bowel tissue sampling is needed for diagnosis. [2][18]"
    },
    {
      "question": "Do 5-aminosalicylates have a role in Crohn disease?",
      "answer": "The cited British Society of Gastroenterology guideline concludes that 5-aminosalicylates have little to no role in Crohn disease management and finds no compelling evidence for postoperative maintenance use. [3]"
    },
    {
      "question": "When should surgery be discussed in Crohn disease?",
      "answer": "Discuss surgery for localized disease and for elective indications such as dysplasia or malignancy, refractory disease, or intolerance to long-term immunosuppression. Perforation, refractory bleeding, and toxic megacolon require emergency surgical management. [2]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "British Society of Gastroenterology consensus guidelines ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/68/Suppl_3/s1",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com"
    },
    {
      "number": 2,
      "title": "Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00112-2/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 3,
      "title": "British Society of Gastroenterology guidelines on ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/74/Suppl_2/s1",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com"
    },
    {
      "number": 4,
      "title": "Inflammatory bowel disease: recent developments",
      "detail": "adc.bmj.com",
      "url": "https://adc.bmj.com/content/archdischild/early/2023/07/19/archdischild-2023-325668.full.pdf",
      "authors": "adc.bmj.com",
      "host": "adc.bmj.com"
    },
    {
      "number": 5,
      "title": "Rise of precision medicine: can it deliver on its promise in ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/75/1/176",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com"
    },
    {
      "number": 6,
      "title": "Chronic pouchitis: what every gastroenterologist needs to ...",
      "detail": "fg.bmj.com",
      "url": "https://fg.bmj.com/content/16/2/143",
      "authors": "fg.bmj.com",
      "host": "fg.bmj.com"
    },
    {
      "number": 7,
      "title": "Supplementary appendix",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/cms/10.1016/S2468-1253(23)00193-0/attachment/f413b70e-7d55-4d3b-97b2-9d97d36b61ed/mmc1.pdf",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 8,
      "title": "The cost of inflammatory bowel disease in high-income ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00003-1/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 9,
      "title": "De-escalation of immunomodulator and biological therapy ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30186-4/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 10,
      "title": "Using clinical factors to predict treatment outcomes and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2210740126001154",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 11,
      "title": "Core indicators of an evaluation and guidance system for ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2589537022001122",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 12,
      "title": "Definitions, diagnosis, management, and outcomes of ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2468125325003474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 13,
      "title": "AGA Medical Position Statement on the Diagnosis and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0016508509022021",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 14,
      "title": "Crohn's Disease: Diagnosis and Management : American Family Physician",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/00000405-202608000-00012",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 15,
      "title": "3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management | Journal of Crohn's and Colitis | Oxford Academic",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/11/1/3/2456546",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 16,
      "title": "European evidence based consensus for endoscopy in inflammatory bowel disease | Journal of Crohn's and Colitis | Oxford Academic",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/7/12/982/446087",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 17,
      "title": "Optimising monitoring in the management of Crohn's disease",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/7/8/653/499880",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 18,
      "title": "Definitions and diagnosis | Journal of Crohn's and Colitis",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/4/1/7/402141",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 19,
      "title": "Treatment Pathways Leading to Biologic Therapies... : Clinical and Translational Gastroenterology",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ctg/fulltext/2020/02000/treatment_pathways_leading_to_biologic_therapies.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 20,
      "title": "Systematic Review and Meta-analysis : Inflammatory Bowel Diseases",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/00054725-201708000-00009",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 21,
      "title": "Update in Medical Treatment of Crohn's Disease",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/jcge/fulltext/2000/12000/update_in_medical_treatment_of_crohn_s_disease.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 22,
      "title": "Crohn's Overview of Comments",
      "detail": "www.ema.europa.eu",
      "url": "https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf",
      "authors": "www.ema.europa.eu",
      "host": "www.ema.europa.eu"
    },
    {
      "number": 23,
      "title": "Biomarkers of Inflammation in Inflammatory Bowel Disease",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085%2815%2900938-5/fulltext",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org"
    },
    {
      "number": 24,
      "title": "Measurement of Fecal Calprotectin Improves Monitoring ...",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085(15)00111-0/fulltext",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "British Society of Gastroenterology consensus guidelines ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/68/Suppl_3/s1",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com",
      "snippet": "high-quality research is required to support and advance future clinical practice in UC and Crohn’s disease. [...] ### 4.3 Initial treatment of moderate to severe ileocolonic Crohn’s disease\n\n#### 4.3.1 Corticosteroids\n\nStatement 37. We recommend that moderate to severely active uncomplicated lumina",
      "score": 0.643173
    },
    {
      "number": 2,
      "title": "Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00112-2/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "PubMed\n\nGoogle Scholar\n\n ACG clinical guidelines recommend that video CE is a useful adjunct in the diagnosis of small-bowel CD in patients with a high index of suspicion of disease. Deep enteroscopy is not a part of routine diagnostic testing in patients with suspected CD, but may provide additiona",
      "score": 0.5852203
    },
    {
      "number": 3,
      "title": "British Society of Gastroenterology guidelines on ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/74/Suppl_2/s1",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com",
      "snippet": "gastroenterology and proposed a pathway to support this.694 A topical review on transition was also published by European Crohn’s and Colitis Organisation (ECCO) in 2017 with 14 practice points highlighted.695 The ECCO document was perhaps a little less process-orientated and a little more patient-o",
      "score": 0.487918
    },
    {
      "number": 4,
      "title": "Inflammatory bowel disease: recent developments",
      "detail": "adc.bmj.com",
      "url": "https://adc.bmj.com/content/archdischild/early/2023/07/19/archdischild-2023-325668.full.pdf",
      "authors": "adc.bmj.com",
      "host": "adc.bmj.com",
      "snippet": "OPTIMAL MANAGEMENT STRATEGIES Providing optimal outcomes requires optimal management strat-egies. This is best delivered across clinical care networks with careful monitoring of outcomes in order that processes and treat-ments can be reviewed, updated and improved to enhance clin-ical care. Multidis",
      "score": 0.44044575
    },
    {
      "number": 5,
      "title": "Rise of precision medicine: can it deliver on its promise in ...",
      "detail": "gut.bmj.com",
      "url": "https://gut.bmj.com/content/75/1/176",
      "authors": "gut.bmj.com",
      "host": "gut.bmj.com",
      "snippet": "### Commonly used endpoint definitions\n\n#### Singular endpoints\n\nClinical response\n\nCrohn’s disease (CD): Reduction of Crohn’s Disease Activity Index (CDAI) by ≥70 points,125 reduction of patient-reported outcome (PRO)2 (absolute stool frequency ×2; pain score ×5) by ≥8.126\n\nUC: Reduction of partial",
      "score": 0.20018251
    },
    {
      "number": 6,
      "title": "Chronic pouchitis: what every gastroenterologist needs to ...",
      "detail": "fg.bmj.com",
      "url": "https://fg.bmj.com/content/16/2/143",
      "authors": "fg.bmj.com",
      "host": "fg.bmj.com",
      "snippet": "Janus kinase (JAK) inhibitors such as tofacitinib and upadacitinib are used in UC and CD, but previous research has shown little to no efficacy in treating chronic pouchitis.68 69 Large-scale studies are needed to ensure their efficacy and safety in managing pouchitis. This ECCO-CONFER project retro",
      "score": 0.0865164
    },
    {
      "number": 7,
      "title": "Supplementary appendix",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/cms/10.1016/S2468-1253(23)00193-0/attachment/f413b70e-7d55-4d3b-97b2-9d97d36b61ed/mmc1.pdf",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "Ustekinumab as induction and maintenance therapy for. Crohn's disease. New England journal of medicine, 375(20), 1946-1960. 148. Feagan",
      "score": 0.49348235
    },
    {
      "number": 8,
      "title": "The cost of inflammatory bowel disease in high-income ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00003-1/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "by J Burisch · 2023 · Cited by 255 — Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases Expert Rev Clin Immunol. 2019; Crohn's disease patients:",
      "score": 0.48850358
    },
    {
      "number": 9,
      "title": "De-escalation of immunomodulator and biological therapy ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30186-4/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "by TP Chapman · 2020 · Cited by 100 — Here, we review the current evidence surrounding de-escalation of immunomodulator and biological therapy in Crohn's disease and ulcerative colitis.",
      "score": 0.35160094
    },
    {
      "number": 10,
      "title": "Using clinical factors to predict treatment outcomes and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2210740126001154",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "ACG Clinical guideline: management of Crohn's Disease ... AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease.",
      "score": 0.65279555
    },
    {
      "number": 11,
      "title": "Core indicators of an evaluation and guidance system for ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S2589537022001122",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by Y Chen · 2022 · Cited by 11 — ACG clinical guideline: management of Crohn's disease in adults ... disease: expert review from the clinical practice updates committee of the AGA institute.",
      "score": 0.6490677
    },
    {
      "number": 12,
      "title": "Definitions, diagnosis, management, and outcomes of ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2468125325003474",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by NA Cohen · 2026 · Cited by 1 — ECCO guidelines recommend upper endoscopy in patients with newly diagnosed Crohn's disease or patients with inflammatory bowel disease (IBD) unclassified,",
      "score": 0.51662046
    },
    {
      "number": 13,
      "title": "AGA Medical Position Statement on the Diagnosis and ...",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0016508509022021",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "by FA Farraye · 2010 · Cited by 619 — Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. 2013, Journal of Crohn S and Colitis.",
      "score": 0.42691937
    },
    {
      "number": 14,
      "title": "Crohn's Disease: Diagnosis and Management : American Family Physician",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/00000405-202608000-00012",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Crohn's disease is a chronic inflammatory condition that affects the gastrointestinal tract and often causes extraintestinal manifestations. Diarrhea, abdominal pain, fatigue, weight loss, and fever are common symptoms. Children may present with changes in growth velocity or delayed puberty. Initial",
      "score": 0.6864757
    },
    {
      "number": 15,
      "title": "3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management | Journal of Crohn's and Colitis | Oxford Academic",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/11/1/3/2456546",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "calprotectin is a sensitive marker that predicts relapse in patients with CD.227–230 Weaknesses of calprotectin in CD include its diminished value in patients with CD restricted to the small bowel,224 an imperfect correlation with transmural inflammation and an absence of uniform thresholds. In summ",
      "score": 0.595987
    },
    {
      "number": 16,
      "title": "European evidence based consensus for endoscopy in inflammatory bowel disease | Journal of Crohn's and Colitis | Oxford Academic",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/7/12/982/446087",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "treated with anti-TNFα agents. Neither the clinical indices nor CRP were reliable at identifying endoscopic remission, however raised calprotectin had a sensitivity of 84% and specificity of 74%. In the study by D'Haens et al.54 a calprotectin level of ≤ 250 μg/g predicted endoscopic remission (CDEI",
      "score": 0.466433
    },
    {
      "number": 17,
      "title": "Optimising monitoring in the management of Crohn's disease",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/7/8/653/499880",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by P Papay · 2013 · Cited by 145 — faecal calprotectin is evaluated 3 months post surgery, with consideration of an earlier endoscopy if an increase is seen, and then after the first endoscopy",
      "score": 0.45522344
    },
    {
      "number": 18,
      "title": "Definitions and diagnosis | Journal of Crohn's and Colitis",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ecco-jcc/article/4/1/7/402141",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "by G Van Assche · 2010 · Cited by 1437 — Capsule endoscopy and enteroscopy with biopsy by a push endoscope are safe and useful procedures for diagnosis of CD in selected patients. The aspects",
      "score": 0.35374123
    },
    {
      "number": 19,
      "title": "Treatment Pathways Leading to Biologic Therapies... : Clinical and Translational Gastroenterology",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ctg/fulltext/2020/02000/treatment_pathways_leading_to_biologic_therapies.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Because UC and CD are characterized by a relapsing and remitting course, clinical management is complex, with a broad range of therapies available for induction and maintenance of disease control (9). Pharmacologic treatment for mild to moderate disease begins with aminosalicylates (for UC), cortico",
      "score": 0.5752307
    },
    {
      "number": 20,
      "title": "Systematic Review and Meta-analysis : Inflammatory Bowel Diseases",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/00054725-201708000-00009",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "### Conclusions:\n\nThe combination of ADA and immunomodulators does not seem superior to ADA monotherapy for induction and maintenance of remission and response in Crohn's disease. Combination therapy is associated with lower immunogenicity. Analyses associating combination therapy with better induct",
      "score": 0.5313802
    },
    {
      "number": 21,
      "title": "Update in Medical Treatment of Crohn's Disease",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/jcge/fulltext/2000/12000/update_in_medical_treatment_of_crohn_s_disease.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "New biologic therapy has been developed to better target the immune mediators that are active in Crohn's disease. Infliximab is the first of the biologic agents",
      "score": 0.41392776
    },
    {
      "number": 22,
      "title": "Crohn's Overview of Comments",
      "detail": "www.ema.europa.eu",
      "url": "https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf",
      "authors": "www.ema.europa.eu",
      "host": "www.ema.europa.eu",
      "snippet": "the continuous nature of Crohn’s disease should also be clearly stated in the introduction to this guidance. Agreed. A sentence has been added. • The biomarkers of inflammation (such as CRP and ESR) do not correlate well with the clinical expression of active disease in individual patients and their",
      "score": 0.4398682
    },
    {
      "number": 23,
      "title": "Biomarkers of Inflammation in Inflammatory Bowel Disease",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085%2815%2900938-5/fulltext",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org",
      "snippet": "by BE Sands · 2015 · Cited by 543 — A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease J Crohns Colitis.",
      "score": 0.57780564
    },
    {
      "number": 24,
      "title": "Measurement of Fecal Calprotectin Improves Monitoring ...",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085(15)00111-0/fulltext",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org",
      "snippet": "by EK Wright · 2015 · Cited by 370 — In conclusion, fecal calprotectin measurement has a potentially valuable role to play in monitoring Crohn's disease patients after intestinal resection. In the",
      "score": 0.52597815
    }
  ],
  "publishedAt": "2026-08-21T01:35:12.709511+00:00",
  "updatedAt": "2026-08-21T01:35:12.709511+00:00",
  "readingMinutes": 6,
  "slug": "crohn-disease"
}